Azienda Ulss 6 Euganea

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease1 trial
• Kidney cancer1 trial
• Lung cancer1 trial
• Peripheral artery disease1 trial
• Stroke1 trial

Phase

• Phase 32 trials
• Phase 2/31 trial

Status

• Not yet recruiting3 trials

Lead sponsor

• Fondazione IRCCS Istituto Nazionale Dei Tumori1 trial
• Population Health Research Institute1 trial
• Universita' Degli Studi Di Torino1 trial

Running trials

• Not yet recruiting

  DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”

  2026-525268-16-00· Phase 2/3· Universita' Degli Studi Di Torino· Source

• Not yet recruiting

  Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.

  2025-523903-31-00· Phase 3· Fondazione IRCCS Istituto Nazionale Dei Tumori· Source

• Recruiting

  Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

  NCT04774159· Phase 3· Population Health Research Institute· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Peripheral artery disease1 recruiting
• Stroke1 recruiting